According to GlobalData’s medical device pipeline database, 113 Inborn Gene or Chromosome Alterations devices are in various stages of development globally. GlobalData’s report Inborn Gene or Chromosome Alterations provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 21 are in active development, while the remaining 92 are in an inactive stage of development. There are 12 products in the early stages of development, and the remaining nine are in the late stages of development.
Genetic tests to detect monogenetic disorders (like Cystic Fibrosis, Haemochromatosis, Prothrombin Mutation etc), polygenetic disorders (like Asthma , Atherosclerosis, Diabetes, Hypertension, Osteoporosis, etc), chromosomal disorders (like Down’s Syndrome, Edwards Syndrome etc), polymorphisms (like HLA-Typing etc).
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Inborn Gene or Chromosome Alterations pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Inborn Gene or Chromosome Alterations devices. Overall, most of these Inborn Gene or Chromosome Alterations pipeline devices are being developed by private entities.
Key players involved in the active development of Inborn Gene or Chromosome Alterations include Oxford Biodynamics, Population Bio, CareDx, AutoGenomics, French National Institute of Health and Medical Research, Sapien Biosciences, Quest Diagnostics, Strand Life Sciences, Suzhou Basecare Medical and University of Central Florida.
For a complete picture of the developmental pipeline for Inborn Gene or Chromosome Alterations devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
